FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1604916622> ?p ?o ?g. }

• W1604916622 abstract "Thyroid nodules (TN) are common in the adult population. Some physicians use suppressive levothyroxine (LT4) therapy to achieve a reduction in the number and volume of TN. In addition, minimally invasive treatments, such as percutaneous ethanol injection (PEI) sclerotherapy, laser photocoagulation (LP), and microwave (MW), radiofrequency (RF) and high-intensity focused ultrasound (HIFU) ablation, have been proposed, especially for pressure symptoms and cosmetic complaints, as an alternative to surgery. However, the risk to benefit ratio of all treatments for benign TN is currently unknown.To assess the effects of LT4 or minimally invasive therapies (PEI, LP, and RF/HIFU/MW ablation) on benign TN.We identified studies from computerised searches of The Cochrane Library, MEDLINE, EMBASE and LILACS (all performed up to April 2014). We also searched trial registers, examined reference lists of included randomised controlled trials (RCTs) and systematic reviews, and contacted study authors.We included studies if they were RCTs of LT4, PEI, LP, RF, HIFU or MW therapy in participants with an established diagnosis of benign TN. We excluded trials investigating the prevention of recurrence of thyroid disease after surgery, irradiation or treatment with radioiodine.Two review authors independently extracted data, assessed studies for risk of bias and evaluated overall study quality utilising the GRADE instrument. We assessed the statistical heterogeneity of included studies by visually inspecting forest plots and quantifying the diversity using the I² statistic. We synthesised data using random-effects model meta-analysis or descriptive analysis, as appropriate.Thirty-one studies randomised 2952 outpatients to investigate the effects of different therapies on benign TN. Studies on LT4, PEI, LP and RF ablation therapy randomised 2083, 607, 192 and 70 participants, respectively. We found no RCTs of HIFU or MW ablation therapy in benign TN. The duration of treatment varied according to the applied therapies: up to five years for LT4 and one to three PEI ablations, one to three LP sessions and one or two RF sessions. Median follow-up was 12 months for LT4 and six months for minimally invasive therapies. Evidence was of low-to-moderate quality, and risk of performance and detection bias for subjective outcomes was high in most trials.No study evaluated all-cause mortality or health-related quality of life. Only one LT4 study provided some data on the development of thyroid cancer, reporting no abnormal cytological findings. One LP study provided limited information on costs of treatment.LT4 compared with no treatment or placebo was associated with a nodule volume reduction of 50% or more in 16% compared with 10% of participants after 6 to 24 months of follow-up (risk ratio (RR) 1.57 (95% confidence interval (CI) 1.04 to 2.38); P = 0.03; 958 participants; 10 studies; moderate-quality evidence). Pressure symptoms or cosmetic complaints were not investigated in LT4 studies. LT4 therapy was generally well tolerated: three studies provided quantitative data on signs and symptoms of hyperthyroidism, which were observed in 25% of LT4-treated versus 7% of placebo-treated participants at 12 to 18 months of follow-up (269 participants; 3 trials; low-quality evidence).PEI compared with cyst aspiration only was associated with a nodule volume reduction of 50% or more in 83% compared with 44% of participants after 1 to 24 months of follow-up (RR 1.83 (95% CI 1.32 to 2.54); P = 0.0003; 105 participants; 3 studies; low-quality evidence). Improvements in neck compression symptoms after 6 to 12 months of follow-up were seen in 78% of participants receiving PEI versus 38% of those in comparator groups. No reliable summary effect estimate could be established, RR ranged from 1.0 to 3.06 in favour of PEI (370 participants; 3 trials; low-quality evidence). In all trials, participants experienced periprocedural cervical tenderness and light-to-moderate pain usually lasting from minutes to several hours. As a result of the PEI procedure, 26% of participants reported slight-to-moderate pain compared with 12% of those receiving cyst aspiration only (RR 1.78 (95% CI 0.62 to 5.12); P = 0.28; 104 participants; 3 studies; low-quality evidence).One study comparing LP with LT4 showed a nodule volume reduction of 50% or more in favour of LP after 12 months of follow-up in 33% of LP participants versus 0% of LT4 participants, respectively (62 participants; 1 trial; low-quality evidence). A total of 82% of LP-treated versus 0% of untreated participants showed improvements in pressure symptoms after 6 to 12 months of follow-up (RR 26.65 (95% CI 5.47 to 129.72); P < 0.0001; 92 participants; 3 trials; low-quality evidence). Around 20% of LP-treated participants reported light-to-moderate cervical pain lasting 48 hours or more (97 participants; 3 trials; low-quality evidence).One trial with 40 participants, comparing RF with no treatment, resulted in a mean nodule volume reduction of 76% in the RF group compared with 0% of those in the no-treatment group at six months of follow-up (low-quality evidence). These RF-treated participants had fewer pressure symptoms and cosmetic complaints after 12 months of follow-up compared with untreated participants (a 2.8 decrease versus a 1.1 increase on a six-point scale, respectively, with higher values indicating more severe symptoms; low-quality evidence). All participants complained of pain and discomfort during RF, which disappeared when the energy was reduced or turned off (low-quality evidence).No study evaluated all-cause mortality, health-related quality of life or provided systematic data on the development of thyroid cancer. Longest follow-up was five years and median follow-up was 12 months. Nodule volume reductions were achieved by PEI, LP and RF, and to a lesser extent, by LT4. However, the clinical relevance of this outcome measure is doubtful. PEI, LP and RF led to improvements in pressure symptoms and cosmetic complaints. Adverse events such as light-to-moderate periprocedural pain were seen after PEI, LP and RF. Future studies should focus on patient-important outcome measures, especially health-related quality of life, and compare minimally invasive procedures with surgery. RCTs with follow-up periods of several years and good-quality observational studies are needed to provide evidence on the development of thyroid cancer, all-cause mortality and long-term adverse events." @default.
• W1604916622 created "2016-06-24" @default.
• W1604916622 creator A5021516493 @default.
• W1604916622 creator A5025682200 @default.
• W1604916622 creator A5079939649 @default.
• W1604916622 date "2014-06-18" @default.
• W1604916622 modified "2023-10-14" @default.
• W1604916622 title "Levothyroxine or minimally invasive therapies for benign thyroid nodules" @default.
• W1604916622 cites W153757487 @default.
• W1604916622 cites W1566946035 @default.
• W1604916622 cites W159071236 @default.
• W1604916622 cites W1865932333 @default.
• W1604916622 cites W1942475370 @default.
• W1604916622 cites W1965011810 @default.
• W1604916622 cites W1968542306 @default.
• W1604916622 cites W1972653970 @default.
• W1604916622 cites W1977408463 @default.
• W1604916622 cites W1982481950 @default.
• W1604916622 cites W1987429747 @default.
• W1604916622 cites W1989579274 @default.
• W1604916622 cites W1991718463 @default.
• W1604916622 cites W1991904056 @default.
• W1604916622 cites W1992692011 @default.
• W1604916622 cites W1993266911 @default.
• W1604916622 cites W1997913901 @default.
• W1604916622 cites W2000450116 @default.
• W1604916622 cites W2000886517 @default.
• W1604916622 cites W2006175454 @default.
• W1604916622 cites W2007312287 @default.
• W1604916622 cites W2012127421 @default.
• W1604916622 cites W2012996608 @default.
• W1604916622 cites W2014246292 @default.
• W1604916622 cites W2015987010 @default.
• W1604916622 cites W2020664508 @default.
• W1604916622 cites W2022600178 @default.
• W1604916622 cites W2023295437 @default.
• W1604916622 cites W2026199326 @default.
• W1604916622 cites W2031901280 @default.
• W1604916622 cites W2033822547 @default.
• W1604916622 cites W2033882181 @default.
• W1604916622 cites W2034948739 @default.
• W1604916622 cites W2036602023 @default.
• W1604916622 cites W2039377912 @default.
• W1604916622 cites W2039557988 @default.
• W1604916622 cites W2042330026 @default.
• W1604916622 cites W2043281621 @default.
• W1604916622 cites W2043321920 @default.
• W1604916622 cites W2050921960 @default.
• W1604916622 cites W2053789979 @default.
• W1604916622 cites W2056947096 @default.
• W1604916622 cites W2057907205 @default.
• W1604916622 cites W2059027713 @default.
• W1604916622 cites W2059126476 @default.
• W1604916622 cites W2065796668 @default.
• W1604916622 cites W2065884156 @default.
• W1604916622 cites W2067510257 @default.
• W1604916622 cites W2069672358 @default.
• W1604916622 cites W2075211341 @default.
• W1604916622 cites W2078280483 @default.
• W1604916622 cites W2081296496 @default.
• W1604916622 cites W2081970311 @default.
• W1604916622 cites W2084888471 @default.
• W1604916622 cites W2085893775 @default.
• W1604916622 cites W2091200159 @default.
• W1604916622 cites W2091550153 @default.
• W1604916622 cites W2091573019 @default.
• W1604916622 cites W2093730611 @default.
• W1604916622 cites W2097932626 @default.
• W1604916622 cites W2098156528 @default.
• W1604916622 cites W2098923148 @default.
• W1604916622 cites W2101995865 @default.
• W1604916622 cites W2102355184 @default.
• W1604916622 cites W2102969997 @default.
• W1604916622 cites W2105497212 @default.
• W1604916622 cites W2105940178 @default.
• W1604916622 cites W2108116635 @default.
• W1604916622 cites W2112959681 @default.
• W1604916622 cites W2114804629 @default.
• W1604916622 cites W2114851421 @default.
• W1604916622 cites W2116542352 @default.
• W1604916622 cites W2116903565 @default.
• W1604916622 cites W2117537013 @default.
• W1604916622 cites W2119605658 @default.
• W1604916622 cites W2123252026 @default.
• W1604916622 cites W2125435699 @default.
• W1604916622 cites W2126670362 @default.
• W1604916622 cites W2126930838 @default.
• W1604916622 cites W2129585203 @default.
• W1604916622 cites W2133511639 @default.
• W1604916622 cites W2134393467 @default.
• W1604916622 cites W2136274926 @default.
• W1604916622 cites W2138322650 @default.
• W1604916622 cites W2138490081 @default.
• W1604916622 cites W2140980707 @default.
• W1604916622 cites W2144672245 @default.
• W1604916622 cites W2147416156 @default.
• W1604916622 cites W2148113299 @default.
• W1604916622 cites W2150574033 @default.
• W1604916622 cites W2152497658 @default.
• W1604916622 cites W2158145461 @default.

• next